Maurizio Bonacini, M.D. , Scientist; Transplant Hepatologist at the Hepatology and Gastroenterology Research Center, CPMC

California Pacific CURRENTS: The online journal of CPMC Research Institute

Improving the treatment of hepatitis and other liver diseases
  • clinical and laboratory features of subjects with liver injury attributed to anti-TNF-α agents

    The table above shows the presenting clinical and laboratory features of 6 DILIN subjects with liver injury attributed to anti-TNF-α agents.

    Abbreviations:  Alk Phos, alkaline phosphatase; ALT, alanine aminotransferase; BMI, body mass index; DILI, drug-induced liver injury; DILIN, US Drug Induced Liver Injury Network; INR, international normalized ratio; R, ratio of (serum ALT / upper limit of normal for ALT) divided by (Alk Phos / upper limit of normal for Alk Phos).

    Source: Ghabril M, Bonkovsky HL, Kum C, Davern T, Hayashi PH, Kleiner DE, Serrano J, Rochon J, Fontana RJ, and Bonacini M, for the U.S. Drug-Induced Liver Injury Network. Liver Injury From Tumor Necrosis Factor-α Antagonists: Analysis of Thirty-four Cases. Clinical Gastroenterology and Hepatology 2013;11:558–564. (Table 1)

+

Research Overview

  • Dr. Bonacini pursues clinical research in liver fibrosis, drug-induced liver injury, hepatitis B and C therapy, and clostridium difficile infection after liver transplants.
  • He is a principal investigator on studies investigating the influence of HIV infection on chronic hepatitis B and C infection, efficacy and safety of new therapies for hepatitis B and C, and hepatitis C persistence and pathogenesis.
  • Dr. Bonacini’s research has been published in peer-reviewed journals including The American Journal of Gastroenterology, Journal of Clinical Gastroenterology, Archives of Internal Medicine, and The American Journal of Medicine.

Training
 

Dr. Bonacini obtained his M.D. from the Université Catholique de Louvain School of Medicine in Brussels, Belgium. He completed an internship and medical residency at Booth Memorial Medical Center in New York (NY), and two fellowships: one in gastroenterology at Los Angeles County-University of Southern California Medical Center and the other in hepatology at the University of Southern California in Los Angeles, California.


 

Publication Search

Publications

Bonacini M, Shetler K, Yu I, Osorio RC, Osorio RW, Features of Patients With Severe Hepatitis Due to Mushroom Poisoning and Factors Associated With Outcome. Clin Gastroenterol Hepatol

French JB, Bonacini M, Ghabril M, Foureau D, Bonkovsky HL, Hepatotoxicity Associated with the Use of Anti-TNF-α Agents. Drug Saf

Usachov V, Urban TJ, Fontana RJ, Gross A, Iyer S, Omary MB, Strnad P, Drug-Induced Liver Injury Network., Prevalence of genetic variants of keratins 8 and 18 in patients with drug-induced liver injury. BMC Med

Naggie S, Cooper C, Saag M, Workowski K, Ruane P, Towner WJ, Marks K, Luetkemeyer A, Baden RP, Sax PE, Gane E, Santana-Bagur J, Stamm LM, Yang JC, German P, Dvory-Sobol H, Ni L, Pang PS, McHutchison JG, Stedman CA, Morales-Ramirez JO, Bräu N, Jayaweera D, Colson AE, Tebas P, Wong DK, Dieterich D, Sulkowski M, ION-4 Investigators., Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med

Sulkowski MS, Naggie S, Lalezari J, Fessel WJ, Mounzer K, Shuhart M, Luetkemeyer AF, Asmuth D, Gaggar A, Ni L, Svarovskaia E, Brainard DM, Symonds WT, Subramanian GM, McHutchison JG, Rodriguez-Torres M, Dieterich D, PHOTON-1 Investigators., Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA

Bonacini M, Ghabril M, Bonkovsky HL, Hepatotoxicity of anti-TNF agents. Dig Dis Sci

VIEW ALL
Maurizio Bonacini, M.D. , Scientist; Transplant Hepatologist at the Hepatology and Gastroenterology Research Center, CPMC
Primary Research Interests
  • Liver fibrosis
  • Drug-induced liver injury
  • Treatment of hepatitis B and C

Liver Failure and Liver Transplant Clinical Trials